Form 4: Pulse Biosciences Director Robert Duggan Increases Stake Through Stock Purchases

Pulse Biosciences director Robert Duggan acquired additional shares of common stock through open market purchases, increasing his total holdings.

Summary

• Robert Duggan, a director and 10% owner of Pulse Biosciences, Inc., has reported purchasing additional shares of the company's common stock.
• On December 11, 2024, Duggan acquired 6,054 shares at a price of $16.74 per share and 50,000 shares at $17.42 per share.
• Following these transactions, Duggan directly owns 42,228,057 shares of Pulse Biosciences common stock.
• Additionally, Duggan indirectly owns 561,089 shares through Genius 24C Inc. and 400,877 shares through Blazon Corporation, both entities where he is the sole shareholder.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the director's purchase of shares suggests confidence in the company, but it's a routine filing and not a major event.

Positives

• The director's purchase of shares indicates confidence in the company's future prospects.
• The increased stake by a major shareholder could be seen as a positive signal to the market.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The reported transactions are typical for directors and major shareholders who often adjust their holdings based on their investment strategies and company outlook.
• Similar filings can be seen across the biotechnology sector, with directors and officers regularly buying or selling shares of their companies.

Stakeholder Impact

• The increased stake by a director may positively influence investor confidence.
• The transactions do not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Pulse Biosciences, Robert Duggan, insider trading, stock purchase, beneficial ownership, PLSE, director